Kalaris Therapeutics, Inc.
KLRS
$5.54
$0.071.28%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | |||
|---|---|---|---|---|---|
| Net Income | 68.77% | -100.88% | -199.27% | ||
| Total Depreciation and Amortization | -- | -- | -- | ||
| Total Amortization of Deferred Charges | -- | -100.00% | -76.54% | ||
| Total Other Non-Cash Items | -98.26% | 15.88% | 31.95% | ||
| Change in Net Operating Assets | -100.76% | -934.88% | 213.01% | ||
| Cash from Operations | -161.91% | -215.76% | -64.59% | ||
| Capital Expenditure | -- | -- | -- | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -- | -- | -- | ||
| Cash from Investing | -- | -- | -- | ||
| Total Debt Issued | -- | -100.00% | 50.21% | ||
| Total Debt Repaid | -- | -- | -- | ||
| Issuance of Common Stock | -- | -- | -- | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -- | 100.00% | 1,995,440.00% | ||
| Cash from Financing | -100.00% | -100.00% | 1,530.45% | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | -964.24% | -1,339.03% | 4,750.63% | ||